Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck (NYSE:MRK) announced the opening of a new $1 billion vaccine manufacturing facility in Durham, North Carolina, a major development aligning with the company's broader $12 billion U.S. investment ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Great investments are even better and more fruitful when you can buy them at a discount. Lots of investors enjoy keeping an ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

另一项进展是，JMP Securities在强劲的第四季度业绩超出预期后，维持Halozyme的"市场表现优于大盘"评级，将股票目标价提高至78美元。H.C.